Field trials were conducted on two groups of calves, numbering 134 and 168 respectively, to investigate theprophylactic efficacy of toltrazuril (triazinon derivatives) against calf coccidiosis, as well as the safety of thedrug. Results showed that the incidence of coccidiosis in the medicated group (n=67, 0.0%) was significantlylower (
P<0.01) than that in the controlled group (n=67, 38.8%). The score of fecal conditions, the excretionrate of diarrheal stool, oocysts, and oocysts per gram of feces (OPG) values of the medicated group wassignificantly lower (
P<0.01) than the controlled group for four weeks of treatment. In the safety tests, noadverse effects attributable to the toltrazuril treatment were observed. However, respiratory symptoms causedby a bacterial infection were observed in 19.0% of the medicated group (n=84) and 26.2% of the controlledgroup (n=84). From these results, it was concluded that a 5% Toltrazuril solution produces excellent prophylacticefficacy against calf coccidiosis, and offers a high degree of availability for clinical use.
View full abstract